UNASSIGNED: The efficacy of @entity1872 was assessed in 50 @entity1 with @entity4018 and @entity417 using the recently revised criteria of the International Working Group for @entity4018 Research and Treatment. According to them, @entity417 response (clinical improvement) is defined as transfusion cessation in transfusion-dependent @entity1 or an Hb increase >2  g/dl in @entity1 without transfusion requirements, both maintained for at least 12  weeks. Median follow-up from @entity1872 start was 36  months (interquartile range [IQR] 19.2-58.8). @entity417 response was achieved in 15 @entity1 (30  %), including 5 of the 27 with transfusion dependency (18.5  %) and 10 of the 23 without transfusion requirements (43.5  %). Median time to response was 5  months (IQR 4-7) and median duration of the response 14  months (IQR 10-21). Among responder @entity1 , 5 discontinued therapy due to @entity137 or personal decision and 1 died from @entity397 while being in response. A trend for worse response was seen in transfusion-dependent @entity1 (p   =   0.055). A platelet increase >50   *   10(9)/l was observed in 3 of 13 @entity882 @entity1 , all of whom had moderate @entity882 . @entity137 was usually moderate, leading to treatment withdrawal in only 4 @entity1 . @entity1872 is effective in 30  % of @entity1 with @entity417 -associated @entity4018 . The responses are less frequent in @entity1 with transfusion dependency.

@entity1872 therapy for the @entity417 of XXXX : assessment of efficacy with current criteria of response and long-term results.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['Anemia', 'anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenic', 'thrombocytopenia'] @entity1872 :: ('MESH:D003613', 'Chemical') :: ['Danazol', 'danazol'] @entity4018 :: ('MESH:D055728', 'Disease') :: ['Myelofibrosis', 'myelofibrosis'] @entity397 :: ('MESH:D012421', 'Disease') :: ['spleen rupture']
@entity4018 :: (MESH:D055728,Disease) :: ['myelofibrosis']
